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Alcohol use disorders and the heart
Ed Day1 & James H. F. Rudd2
Institute for Mental Health, School of Psychology, University of Birmingham, and Honorary Consultant in Addiction Psychiatry, Solihull Integrated Addiction Service, UK1
and Division of Cardiovascular Medicine, University of Cambridge, Honorary Consultant Cardiologist, Addenbrooke’s Hospital, Cambridge, UK2
ABSTRACT
Alcohol use is an important preventable and modiﬁable cause of non-communicable disease, and has complex effects on
the cardiovascular system that vary with dose. Observational and prospective studies have consistently shown a lower risk
of cardiovascular and all-cause mortality in people with low levels of alcohol consumption when compared to abstainers
(the ‘J’-shaped curve). Maximum potential beneﬁt occurs at 0.5 to one standard drinks (7–14 g pure ethanol) per day for
women (18% lower all-causemortality, 95% conﬁdence interval (CI) = 13–22%) and one to two standard drinks (14–28 g
ethanol) per day for men (17% lower all-cause mortality, 95% CI = 15–19%). However, this evidence is contested, and
overall the detrimental effects of alcohol far outweigh the beneﬁcial effects, with the risk of premature mortality increasing
steadily after an average consumption of 10 g ethanol/day. Blood pressure (BP) is increased by regular alcohol consump-
tion in a dose-dependentmanner, with a relative risk for hypertension (systolic BP> 140mmHgor diastolic> 90mmHg)
of 1.7 for 50 g ethanol/day and 2.5 at 100 g/day. Important reductions in BP readings can be expected after as little as
1 month of abstinence from alcohol. Heavy alcohol consumption in a binge pattern is associated with the development
of acute cardiac arrhythmia, even in people with normal heart function. Atrial ﬁbrillation is themost common arrhythmia
associated with chronic high-volume alcohol intake, and above 14 g alcohol/day the relative risk increases 10% for every
extra standard drink (14 g ethanol). Ethanol and its metabolites have toxic effects on cardiac myocytes, and alcoholic car-
diomyopathy (ACM) accounts for a third of all cases of non-ischaemic dilated cardiomyopathy. Screening people drinking
alcohol above low-volume levels and delivering a brief intervention may prevent the development of cardiovascular com-
plications. Although people with established cardiovascular disease show improved outcomes with a reduction to low-
volume alcohol consumption, there is no safe amount of alcohol to drink and patients with ACM should aim for abstinence
in order to optimize medical treatment.
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INTRODUCTION
The harmful effects of alcohol on the heart began to appear
in the medical literature in the 19th century. In 1886 the
director of theMunich Institute of Pathology, Otto Bollinger,
described an alcohol intake of up to 12 litres of beer per day
in a series of 42 cases of cardiac hypertrophy, where many
patients were employed by breweries or in liquor stores [1].
In his 1901 textbook of pathology he described what came
to be known as ‘Plethoric Munich Beer Heart’:
‘idiopathic cardiac hypertrophy usually with dilata-
tion…most frequently found in certain forms of chronic al-
coholism (beer drinkers), whereby plethora and toxic
inﬂuences become effective as pathogenic factors’.
Alcohol use is one of the four most common prevent-
able and modiﬁable causes of major non-communicable
diseases [2], and the globalization of production and mar-
keting of alcohol have increased both the amount of
world-wide consumption and the harms associated with
it [3]. The Alcohol Group of the Global Burden of Disease
(GBD) study found that alcohol was the seventh leading
risk factor for both deaths and disability-adjusted life years
(DALYs), accounting for 2.2% [95% uncertainty interval
(UI) 1.5–3.0] of age-standardized female deaths and 6.8%
(5.8–8.0) of age-standardized male deaths [4]. In 2016 al-
cohol use led to 2.8 million deaths world-wide and was the
leading risk factor for premature death and disability
among people aged 15–49 years, with nearly 9% of all
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attributable DALYs for men and more than 2% for women.
By evaluating all associated relative risks for alcohol use,
the GBD team found that drinking no alcohol minimized
the overall risk to health [4]. However, although it is now
well established that excessive alcohol consumption has
an adverse effect on health and mortality [5], epidemiolog-
ical studies have also suggested some potential beneﬁts of
low levels of consumption, including reductions in coro-
nary heart disease events, ischaemic cerebrovascular
events and cardiovascular and total mortality [6]. These
beneﬁcial effects are contested, and need to be set against
by the negative effects of alcohol contributing to other dis-
eases, accidents and injury and on society as a whole [7].
This review summarizes the epidemiological evidence
for the impact of alcohol on the heart at low, medium
and high levels, before focusing on clinical presentations
of people who consume alcohol at higher levels or in a
binge pattern. There is a particular focus on hypertension,
cardiac arrhythmias and alcoholic cardiomyopathy. Con-
sideration is given to the clinical presentation, pathological
mechanisms, assessment, management and prognosis of
each disorder, as well as the evidence of approaches to
managing alcohol use disorders in this population.
EPIDEMIOLOGY
There are difﬁculties in interpreting data relating to the
health consequences of alcohol consumption. There is a
lack of world-wide consensus as to the amount of alcohol
in a standard alcoholic drink. In the United States a ‘stan-
dard drink’ contains 14 g of pure alcohol, but a ‘unit’ of al-
cohol in the United Kingdom is classiﬁed as 8 g of pure
alcohol, and a standard drink in other countries may con-
tain as much as 20 g of alcohol [8]. This review will adopt
the US deﬁnition of a standard drink unless stated other-
wise. Deﬁnitions of ‘low’, ‘moderate’ and ‘hazardous’ alco-
hol consumption have also varied, but most investigators
have now settled on the following broad deﬁnition: low-risk
drinking = two or fewer drinks/day for men and one
drink/dayor less forwomen,moderate-risk drinking= three
to four drinks/day for men and two to three drinks/day for
women, high-risk drinking = ﬁve or more drinks/day for
men and four or more drinks/day for women and binge
drinking = ﬁve or more drinks/occasion for men and four
or more drinks/occasion for women.
Other factors complicating epidemiological studies of al-
cohol consumption include lack of adequate control for
confounding factors such as cigarette smoking, general
health and socio-economic status; problems with the accu-
rate assessment of alcohol consumption (e.g. assessment
over fewer than 30 days used to assess life-time risk of mor-
bidity and mortality and a failure to assess both quantity
and frequency of consumption); counting both former
drinkers and occasional drinkers as abstainers (which
may make moderate drinkers seem healthier if ill health
is the reason for abstention or occasional drinking); and
combining occasional drinkers with moderate drinkers
[9]. In fact, Rehm has argued that methodological issues
render the utility of cohort studies assessing the relation-
ship between alcohol use and all-causemortality as ‘almost
meaningless’ [10].
ALCOHOL AND CARDIOVASCULAR
MORTALITY: THE J-SHAPED CURVE
Observational and prospective studies have consistently
shown a lower risk of all-cause and cardiovascular mortal-
ity in people with low levels of alcohol consumption when
compared with abstainers, with the highest risks occurring
in people with high levels of consumption (the ‘J-shaped’ or
‘U-shaped’ curve) [5,6,11,12]. Xi and colleagues [5] exam-
ined the association between alcohol consumption and
mortality risk in US adults, using data from the National
Health Interview Surveys of 333247 participants
≥ 18 years of age and categorizing participants according
to self-reported alcohol consumption patterns. Compared
with life-time abstainers, individuals who were classiﬁed
as light or moderate consumers were at reduced risk of
all-cause mortality and cardiovascular mortality, but that
risk increased signiﬁcantly with heavy alcohol consump-
tion. This is seen in the J-shaped curves in Figs 1 and 2.
A meta-analysis of 34 studies including more than a mil-
lion people found a maximum potential beneﬁt at half to
one drink daily for women [18% lower all-cause mortality;
95% conﬁdence interval (CI) = 13–22%] [13]. In men,
maximal potential was seen at one to two drinks/day, with
Figure 1 Dose–response association of current alcohol consumption
with all-causemortality [5]. This ﬁgure is used with permission of Elsevier,
licence number 4591410186372. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
2 Ed Day & James H. F. Rudd
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
an associated reduction of 17% (95% CI = 15–19%) in all-
cause mortality [13]. Consumption of more than 2.5
drinks/day in women and four drinks/day inmenwas asso-
ciatedwith higher death rates in a dose-dependentmanner.
Beverages such as red wine that are high in polyphe-
nols have anti-oxidant, anti-inﬂammatory and antiplatelet
effects. However, ethanol appears to be the main driver of
potential health beneﬁts at low doses and the toxic effects
at high doses. Increased high-density lipoprotein (HDL), re-
duced plasma viscosity, decreased ﬁbrinogen concentra-
tion, increased ﬁbrinolysis, decreased platelet aggregation
and coagulation and enhanced endothelial function are
some of the potentially beneﬁcial mechanisms [11,14].
One criticism of this literature is that low-volume
drinkers may appear healthier only because the ‘ab-
stainers’ with whom they are compared are not drinking
because of pre-existing medical conditions (so-called ‘sick
quitters’) or disease caused by prior high levels of alcohol
consumption. A meta-analysis of 87 studies investigating
alcohol use and mortality risk replicated the classic J-
shaped curve, with low-volume drinkers (1.3–24.9 g
ethanol/day) having reduced mortality risk [relative risk
(RR) = 0.86, 95% CI = 0.83, 0.90] [15]. Occasional
drinkers (< 1.3 g/day) had similar mortality risk
(RR = 0.84, 95% CI = 0.79, 0.89) and former drinkers
had elevated risk (RR = 1.22, 95% CI = 1.14, 1.31). How-
ever, after adjustment for abstainer biases and quality-
related study characteristics, no signiﬁcant reduction in
mortality risk was observed for low-volume drinkers
(RR = 0.97, 95% CI = 0.88, 1.07). Restriction of the anal-
ysis to higher-quality, bias-free studies also failed to show a
reduced mortality risk for low-volume alcohol drinkers.
Risk estimates for occasional drinkers were similar to those
for low- and medium-volume drinkers [15].
Any cardioprotective effect of regular low-volume alco-
hol consumption disappears as soon as episodes of exces-
sive drinking occur. One meta-analysis found that
individuals with irregular heavy drinking episodes of
≥ 60 g pure alcohol per occasion (> 12×/year but
< ﬁve×/week) had a 45% increased morbidity and mortal-
ity risk from ischaemic heart disease compared with indi-
viduals with a regular, moderate alcohol use pattern,
even after adjusting for study type, subject age and
smoking, and exclusion of former drinkers to control for
sick quitters [16]. Overall, the detrimental effects of alcohol
far outweigh the beneﬁcial effects, and the risk of prema-
ture mortality increases steadily after 10 g average daily
consumption in European populations [17].
CLINICAL PRESENTATIONS RELATING
TO THE HEART
When considering the heart and cardiovascular system,
high doses of alcohol can have both acute (depression of
cardiac contractility, cardiac rhythm disturbances, arterial
hypertension, sudden death) and chronic effects (ventricu-
lar dysfunction, atrial dysfunction, arrhythmia, alcoholic
cardiomyopathy and heart failure) [11]. In addition,
chronic high doses of alcohol are associated with the devel-
opment of hypertension, coronary and peripheral athero-
sclerosis, changes in lipid proﬁle and an increased risk of
all forms of stroke. Heavy use of alcohol is often accompa-
nied by the use of other harmful drugs such as tobacco
and cocaine, with synergistic deleterious effects [18,19].
HYPERTENSION
Hypertension is most commonly deﬁned as systolic blood
pressure (BP) > 140 mmHg or diastolic BP > 90 mmHg.
The 2015 GBD study put hypertension as the leading sin-
gle risk factor for morbidity and mortality, responsible for
10.7 million deaths and 211.8 million DALYs world-wide
[20]. Cross-sectional studies, cohort studies and meta-
analytical reviews all point to BP being increased by regu-
lar alcohol consumption in a dose-dependent manner
[6,21]. For example, a multinational meta-analysis showed
a linear relationship between alcohol and BP, with a rela-
tive risk for hypertension of 1.7 for 50 g ethanol/day and
2.5 at 100 g/day [21]. However, gender is an important
modiﬁer of the alcohol threshold level for harm. The Physi-
cian’s Health Study found an apparent protective effect for
women between two and four drinks/week and one
drink/day, but the relationship in men was linear even at
low levels of average consumption [22]. This gender-
speciﬁc result does not have an obvious biological explana-
tion, but one possibility is the ﬁnding that more binge
drinking episodes occur among men at lower levels of
Figure 2 Dose–response association of current alcohol consumption
with cardiovascular disease-speciﬁc (CVD) mortality [5]. This ﬁgure is
used with the permission of Elsevier, licence number 4591410186372.
[Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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average consumption, and these are particularly related to
increases in hypertension incidence and risk [23].
Assessment and treatment of alcohol-associated hyper-
tension follows standard clinical guidelines [24], with am-
bulatory BP monitoring being used to conﬁrm the
diagnosis. A signiﬁcant reduction of alcohol use is essential,
alongside medications such as ACE inhibitors, calcium
channel blockers and diuretics. Important improvements
in BP readings can be expected after as little as 1 month
of abstinence from alcohol, with one study demonstrating
a 7.2 mmHg reduction in mean BP in previously heavy
drinkers [25].
The link between alcohol consumption and hyperten-
sion makes it a key part of the World Health Organization
(WHO) goals to reduce non-communicable disease mortal-
ity. In a meta-analysis of 36 trials, a decrease in alcohol in-
take reduced BP in people who drank more than two
drinks/day, but not in those consuming two or fewer
drinks/day [26]. The American Society of Hypertension
and the International Society of Hypertension recommend
that men limit their alcohol consumption to no more than
two drinks a day and women to no more than one drink a
day [27]. To put the importance of BP control into perspec-
tive at a population level, a 2-mmHg increase in BP in-
creases mortality from stroke by 10% and from coronary
artery disease (CAD) by 7% [28].
ARRHYTHMIA
Heavy alcohol consumption in a binge pattern is associated
with the development of acute cardiac arrhythmia, even in
those with normal heart function. The term ‘holiday heart’
was coined by Ettinger in 1978 to describe ‘an acute car-
diac rhythm and or conduction disturbance associated
with heavy ethanol consumption in a person without
other clinical evidence of heart disease and disappearing
without evident residual, with abstinence’ [29]. The au-
thors noted a seasonal rise in the incidence of arrhythmias
during a period of traditional binge drinking (Christmas
and New Year). Atrial ﬁbrillation (AF) was the most com-
mon arrhythmia noted, but atrial ﬂutter, junctional tachy-
cardia, isolated premature ventricular complexes, isolated
premature atrial complexes, paroxysmal atrial tachycardia
and ventricular tachycardia were also described.
Alcohol may act together with coexistent electrolyte
disturbance and/or acute illnesses such as infections to pro-
duce supraventricular arrhythmias [30]. Sudden death in
alcohol misuse (SUDAM) is increasingly recognized, and
case–series have described heavydrinkerswho die suddenly
with no autopsy ﬁndings other than fatty liver change [31].
There are several possible (but unproven) causes of such
deaths, and a ventricular arrhythmia unmasked by persis-
tent heavy alcohol use is one possibility. When compared
with deaths due to sudden arrhythmic death syndrome,
the SUDAMgroup are signiﬁcantly older and have a 10-fold
greater incidence of fatty liver change [32]. Heavy alcohol
consumption is associated with QT interval prolongation
[33], and alcohol dependence commonly presents along-
side polysubstance use and psychiatric morbidity where
QT-prolonging medications may be part of the clinical pic-
ture, e.g. tricyclic antidepressants, selective serotonin reup-
take inhibitors (SSRIs), lithium and methadone [34]. The
risk of ventricular tachycardia and sudden cardiac death
is lower in individuals with modest alcohol intake (two to
six drinks/week) than those with high intake (21–35
drinks/week) and binge drinkers. This may be attributable
to the protective effects of low-to-moderate alcohol con-
sumption against coronary artery disease as described
above [13]. Arrhythmias may also be manifestations of an
underlying alcoholic cardiomyopathy, and so a holistic car-
diovascular assessment in important.
Daily alcohol intake is associated with a shorter right
atrial effective refractory period (AERP) and increased
atrial ﬂutter in patients less than 60 years old [35]. The
shorter right AERP may allow the right atrium to sustain
a rapid rate in response to an initiating rhythm or allow
propagation of an appropriately timed premature atrial
complex [35]. Atrial ﬁbrillation is the most common ar-
rhythmia associated with chronic high-volume alcohol in-
take. Above a safe threshold of approximately one
drink/day the relative risk of AF increases 10% for each
drink per day [36]. However, it appears that the relation-
ship between chronic alcohol consumption and arrhyth-
mias may be non-linear, involving complex interactions
between dose, drinking pattern, age and sex [34]. For ex-
ample, Psaty found alcohol was inversely related with inci-
dence of AF in older adults with a lower level of drinking
(two to three drinks/week) and a low incidence of binge
drinking [37]. Acute alcohol withdrawal in chronic alco-
hol users can increase cardiac sympathetic activity and re-
duce both heart rate variability and baroreﬂex sensitivity,
promoting cardiac arrhythmias [34].
Assessment and treatment of arrhythmia in patients
who are heavy users of alcohol can be challenging if absti-
nence, or at least a signiﬁcant reduction in intake, is not
achieved [38]. Speciﬁcally, for atrial ﬁbrillation,
anticoagulation to reduce risk of stroke and ventricular
rate control are central to the management strategy. In
some cases, direct current cardioversion or electrophysio-
logically guided ablation techniques may be used, but abla-
tion is known to be less successful in thosewho continue to
drink alcohol, with higher AF relapse rates [39].
ALCOHOLIC CARDIOMYOPATHY
Chronic excessive alcohol consumption is a leading cause
of secondary dilated cardiomyopathy. However, partial or
total recovery of cardiac function can occur if the disease
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is diagnosed early and further alcohol intake is reduced or
halted. Alcoholic cardiomyopathy (ACM) accounts for 33%
of all cases of non-ischaemic dilated cardiomyopathy [40],
and the prevalence is similar in males and females (alcohol
consumption is higher in men, but women are more sus-
ceptible to its effects) [41].
Alcohol can lead to excess free-radical generation and
oxidative stress through at least three mechanisms: etha-
nol metabolism to acetaldehyde and ethyl esters; effects
on anti-oxidant proteins and enzymes; and activation or
alteration of neurohormonal systems such as the sympa-
thetic nervous system or the renin–angiotensin–
aldosterone system (RAAS) [14]. Cardiac myocytes are
excitable cells with complex signalling structures, and as
such are highly sensitive to oxidative stress. Experimental
models of chronic heart damage have many limitations,
but over time heavy alcohol use directly impairs myocar-
dial function by interfering with calcium homeostasis, mi-
tochondrial function, and the structure and function of
contractile proteins [41]. Myocyte apoptosis and necrosis
occurs, and although there is a low rate of regeneration
after cell death, repair mechanisms involving hypertrophy
of remaining cells can initially offset the effect of myocyte
death [11]. However, reduced levels of myoﬁbrillar pro-
teins, combined with the expression of different isoforms
of myosin, result in depressed contraction [41]. These
changes eventually translate into increased left ventricu-
lar dilatation and mass, thinning and left ventricular dys-
function [34]. Genetic variants in certain
proteins/enzymes, variability in nutrition, ethnic and sex
differences may also inﬂuence the occurrence of ACM
[14,41,42] (see Fig. 3).
One-third ofmenwith a total life-time dose of ethanol of
more than 5 kg/kg have echocardiographic evidence of im-
paired diastolic ﬁlling, an effect that persists after correc-
tion for multiple confounders. This is proposed as the
earliest sign of subclinical ACM [11,43]. Long-term high
alcohol consumption is also associated with systolic dys-
function in a dose-dependent way. Prospective studies have
shown that chronic alcohol consumption of more than
100 g/day in men and 80 g/day in women over a period
of 10 years is associated with dose-dependent effects on left
ventricular function [44].
Regular, heavy alcohol use can lead to ACM, character-
ized by dilation and impaired contraction of one or both
ventricles in the presence of normal or reduced ventricular
wall thickness, with no other identiﬁed cause of cardiomy-
opathy [45]. ACM is deﬁned as an acquired dilated cardio-
myopathy associated with long-term heavy alcohol
consumption (> 80 g per day over a period of at least
5 years). Typical histological ﬁndings are myoﬁbrillar ne-
crosis and ﬁbrosis, with reduced myoﬁbrils and giant mito-
chondria, ﬁndings which do not differentiate ACM from
other forms of dilated cardiomyopathy.
Presenting symptoms relate to the reduction in cardiac
output and are the same as chronic cardiac failure of any
aetiology, i.e. shortness of breath on exertion, bilateral
pitting oedema, fatigue, mental confusion, oliguria and
nocturia. Physical examinationmay reveal a raised jugular
venous pressure, third and/or fourth heart sound and a
systolic murmur, and possibly a tachyarrhythmia such as
AF. Diagnosis requires a long history of signiﬁcant alcohol
use and exclusion of other causes of dilated cardiomyopa-
thy. Blood tests such as gamma-glutamyl transferase
(GGT), mean corpuscular volume (MCV), carbohydrate-
deﬁcient transferrin (CDT) and ethyl-gluconide may help
to diagnose alcohol use disorder, coexisting liver disease
and monitor abstinence. N-terminal pro-B-type natriuretic
peptide (NT pro-BNP) levels are increasingly used to make
a diagnosis of heart failure in patients with breathlessness,
andmay be helpful. A chest X-raymay showcardiomegaly,
pulmonary congestion and pleural effusions, depending on
disease severity. An electrocardiogram may reveal
coexisting atrial ﬁbrillation, along with non-speciﬁc ST
and T-wave changes. There are no tell-tale electrocardio-
gram (ECG) features of ACM that can differentiate it from
other causes of cardiomyopathy. Echocardiography is man-
datory for diagnosis and to exclude other causes of heart
failure. Typically, it shows biventricular dilatation and sys-
tolic and diastolic dysfunction. Occasionally, cardiac mag-
netic resonance imaging (MRI) is needed to conﬁrm the
diagnosis if echocardiographic images are suboptimal. Ex-
clusion of contributing coronary artery disease with coro-
nary angiography is often required.
The prevailing wisdom regarding treatment of ACM is
total abstinence from alcohol to allow potential recovery
of cardiac function. Unfortunately, no blood or imaging
biomarkers of potential reversibility have been identiﬁed.
Abstinence has been associated with improved LV function
in small observational studies in some patients (e.g. [46]).
However, Nicolas et al. found signiﬁcant cardiac improve-
ment in both those achieving abstinence and those reduc-
ing consumption to less than 60 g ethanol/day, but cardiac
function deteriorated in thosewho did not change drinking
[47]. As there is no safe amount of alcohol to drink, it is
best to aim for abstinence in the ﬁrst instance.
After abstinence, treatment of ACM should include
beta-blockers, ACE inhibitors, angiotensin receptor antago-
nists and diuretics, following standard guidelines [48]. Pa-
tients with persistent severe ventricular dysfunction
despite optimized pharmacological therapy should be eval-
uated for implantable cardioverter deﬁbrillator (ICD) inser-
tion and heart transplant if considered appropriate. Eating
a balanced diet is important, and any nutritional deﬁcien-
cies should be corrected. Vitamin supplementation with vi-
tamin B12, vitamin B6 and folate may be needed,
particularly for those with sustained heavy alcohol use.
In the largest published follow-up study of patients with
Alcohol and the heart 5
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ACM (n = 94, median follow-up 59 months), approxi-
mately one-third had a poor prognosis, whereas two-thirds
remained clinically stable. Atrial ﬁbrillation, QRS width-
120 msec, and the absence of beta-blocker therapy were
associated with a worse outlook [49].
MANAGEMENT OF ALCOHOL USE
DISORDER AND CARDIAC DISORDERS
Interventions for alcohol use disorders exist along a spec-
trum [50]. Screening people drinking at ‘at-risk’ level and
delivering a brief intervention may prevent the develop-
ment of cardiovascular complications such as hypertension
and arrhythmias. However, despite a strong evidence base
for such interventions [51], they are rarely implemented
in routine medical practice [52]. Excessive consumption
of alcohol is one of a number of modiﬁable causes of health
problems in the developedworld. Asmedical caremoves to-
wards a chronic disease model there have been calls to in-
corporate effective behaviour change strategies into
medical practice, and a number have been identiﬁed for
changing alcohol use [53].
Motivational Interviewing (MI) is a counselling style
that aims to address the problem of ambivalence about
change, and is both person-centred and directional in its fo-
cus on goals such as changes in health behaviours [54]. In
a systematic review and meta-analysis of the efﬁcacy of MI
throughout medical settings, 63% of the main outcome
comparisons yielded statistically signiﬁcant advantages
favouring MI [55]. MI produced a statistically signiﬁcant
and positive impact on amount of alcohol consumed, but
this did not include any studies of populations with cardiac
disease. Unlike other areas of medicine (e.g. surgery [56] or
liver failure [57]), there is little published literature on inter-
ventions tailored to reducing alcohol use in populations
with cardiovascular disease.
Psychosocial interventions are efﬁcacious in treating al-
cohol use disorder [58], and are the mainstay of treatment.
The predominant treatment goal for alcohol dependence
has traditionally been abstinence. Acamprosate and nal-
trexone have been shown to reduce the risk of returning
to drinking when prescribed in conjunction with psychoso-
cial interventions [59], and neither have cardiac-related
contraindications. Disulﬁram works in a different manner
(inhibition of acetaldehyde dehydrogenase enzyme leading
to a build-up of acetaldehyde and associated unpleasant
physical effects), and its deterrent effect can improve the
outcome of treatment when a third party is involved to as-
sist with compliance [60]. At the usual prescribed dose of
200–250mg/day, the disulﬁram-alcohol interaction varies
from mild ﬂushing to distressing nausea, headache, dizzi-
ness and chest tightness. Fatal cases reported in the medi-
cal literature suggest that cardiac causes of death are
common [61]. In the early days of disulﬁram use, patients
were given a test dose of alcohol, and most patients devel-
oped some ECG changes during the reaction (e.g. QT-
prolongation). Hypotension and hypertension are also
common, and the potentially fatal outcome of a
disulﬁram-alcohol reaction in a patient with heart disease
means that disulﬁram is not usually offered to this group.
Abstinence from alcohol is likely to produce the best
outcomes for established hypertension, arrhythmia and
cardiomyopathy, but may not be a feasible or acceptable
goal for many patients. Intervention strategies have now
Figure 3 A summary of the effects of acute and chronic alcohol consumption on the heart and cardiovascular system. The blue boxes and arrows
represent inﬂuences on susceptibility to alcohol-related harm. Adapted from Piano 2017 [14] and Mirijello et al. 2017 [41]. [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
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broadened to include reduction of alcohol intake, and even
alcohol-dependent people with loss of control over the past
12 months can reduce their drinking [62]. Treatment
programmes aiming at harm reduction help to establish
self-determined controlled drinking and use this as a bridge
to long-term abstinence [63,64]. Interventions aiming at
reducing total alcohol consumption and/or modifying the
drinking pattern are associated with positive effects in
harmful, hazardous or alcohol-dependent drinkers [65].
PROGNOSIS
Secondary prevention
People with established cardiovascular disease show im-
proved outcomes with a reduction to low-volume drinking.
Ameta-analysis of 16351 patients with a previous diagno-
sis of CVD found a J-shaped curve with maximal risk at two
drinks/day [66]. A similar relationship exists between alco-
hol and cardiovascular mortality in patients who have ex-
perienced a myocardial infarction [67], and low levels of
alcohol are also associated with less atherosclerotic pro-
gression in coronary artery bypass grafts post-coronary ar-
tery bypass grafting (CABG) [68].
Mortality rates
The mortality risk may decline threefold if a person with a
usual alcohol intake of 96 g ethanol/day cuts down to 36 g
ethanol/day compared with a constant daily intake of 60 g
ethanol/day [69]. In one long-term prospective cohort
study (n = 850), 15% heavy drinking patients (deﬁned as
50 g ethanol or more per drinking occasion or daily drink-
ing) died after 10 years and 39.1% after 20 years, com-
pared to low-volume drinkers consuming less than 50 g
ethanol per drinking occasion less than once per month
(5.3% at 10 years and 19.7% at 20 years) [70]. In con-
trast, signiﬁcantly more relapsed patients (73%) died pre-
maturely at the mean age of 48 years (mainly from heart
attack or heart failure) compared to those without relapses
(30%) in the 16-year observation period.
Conclusions
Although low-volume alcohol consumption (one drink/day
or less for women and two drinks formen)may confer some
beneﬁt in terms of reduced risk of ischaemic heart disease
[71], alcohol use at higher levels is associated with in-
creased cardiovascular risk and premature mortality. Occa-
sional binge drinking (more than ﬁve drinks within a few
hours, with intoxication as intended consequence) reverses
any protection associated with low-volume alcohol con-
sumption. The main cardiovascular effects of long-term al-
cohol consumption are hypertension, cardiac arrhythmia,
cardiomyopathy and heart failure. Treatment for alcohol
use disorder is best focused on abstinence from alcohol, al-
though gains are often achieved by signiﬁcant reduction in
alcohol consumption or changes in pattern of drinking.
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